Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.
Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A.
J Antimicrob Chemother. 2012 Apr;67(4):819-31. Epub 2012 Jan 25.
Related citations
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.
Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA.
J Antimicrob Chemother. 2012 May;67(5):1163-6. Epub 2012 Jan 17.
Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine.
Abbate E, Vescovo M, Natiello M, Cufré M, García A, Gonzalez Montaner P, Ambroggi M, Ritacco V, van Soolingen D.
J Antimicrob Chemother. 2012 Feb;67(2):473-7. Epub 2011 Dec 1.
Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan.
Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Jr.
J Antimicrob Chemother. 2012 Mar;67(3):633-7. Epub 2011 Nov 29.
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.
Chopra S, Matsuyama K, Tran T, Malerich JP, Wan B, Franzblau SG, Lun S, Guo H, Maiga MC, Bishai WR, Madrid PB.
J Antimicrob Chemother. 2012 Feb;67(2):415-21. Epub 2011 Nov 2.
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Saleri N, Dembélé SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, Nacanabo R, Kouanda S, Comelli M, Regazzi M, Matteelli A.
J Antimicrob Chemother. 2012 Feb;67(2):469-72. Epub 2011 Oct 25.
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R.
J Antimicrob Chemother. 2011 Sep;66(9):2075-82. Epub 2011 Jun 28.
Fluoroquinolone-resistant tuberculosis at a medical centre in Taiwan, 2005-10.
Lai CC, Tan CK, Huang YT, Liao CH, Hsueh PR.
J Antimicrob Chemother. 2011 Oct;66(10):2437-8. Epub 2011 Jul 27. No abstract available.
High prevalence of multidrug-resistant tuberculosis in Zunyi, Guizhou Province of China.
Chen L, Li N, Liu M, Zhang J, Zhang H.
J Antimicrob Chemother. 2011 Oct;66(10):2435-7. Epub 2011 Jul 26. No abstract available.
Impaired fitness of Mycobacterium tuberculosis resistant isolates in a cell culture model of murine macrophages.
Rey-Jurado E, Tudó G, Borrell S, Alcaide F, Coll P, Español M, Martín-Casabona N, Mick V, Montemayor M, Moure R, Salvadó M, Vicente E, González-Martín J.
J Antimicrob Chemother. 2011 Oct;66(10):2277-80. Epub 2011 Jul 25.
Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China.
Shi D, Li L, Zhao Y, Jia Q, Li H, Coulter C, Jin Q, Zhu G.
J Antimicrob Chemother. 2011 Oct;66(10):2240-7. Epub 2011 Jul 21.
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Cremades R, Rodríguez JC, García-Pachón E, Galiana A, Ruiz-García M, López P, Royo G.
J Antimicrob Chemother. 2011 Oct;66(10):2281-3. Epub 2011 Jul 6.
Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.
Xu HB, Jiang RH, Li L.
J Antimicrob Chemother. 2011 Aug;66(8):1687-95. Epub 2011 Jun 3. Review.
Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, Dedicoat MJ, Harrison TS, John L, Lipman M, Cooke GS.
J Antimicrob Chemother. 2011 Aug;66(8):1815-20. Epub 2011 Jun 3.
Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania.
van den Boogaard J, Semvua HH, van Ingen J, Mwaigwisya S, van der Laan T, van Soolingen D, Kibiki GS, Boeree MJ, Aarnoutse RE.
J Antimicrob Chemother. 2011 Aug;66(8):1810-4. Epub 2011 Jun 3.
Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics.
Guzman JD, Wube A, Evangelopoulos D, Gupta A, Hüfner A, Basavannacharya C, Rahman MM, Thomaschitz C, Bauer R, McHugh TD, Nobeli I, Prieto JM, Gibbons S, Bucar F, Bhakta S.
J Antimicrob Chemother. 2011 Aug;66(8):1766-72. Epub 2011 May 28.
Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
Ahmad Z, Fraig MM, Pinn ML, Tyagi S, Nuermberger EL, Grosset JH, Karakousis PC.
J Antimicrob Chemother. 2011 Jul;66(7):1560-6. Epub 2011 May 20.
Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
Almeida Da Silva PE, Palomino JC.
J Antimicrob Chemother. 2011 Jul;66(7):1417-30. Epub 2011 May 9. Review.
Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis.
Mena A, Vázquez P, Castro Á, López S, Bello L, Pedreira JD.
J Antimicrob Chemother. 2011 Apr;66(4):951-2. Epub 2011 Jan 22. No abstract available.
Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis.
Martin A, Paasch F, Docx S, Fissette K, Imperiale B, Ribón W, González LA, Werngren J, Engström A, Skenders G, Juréen P, Hoffner S, Del Portillo P, Morcillo N, Palomino JC.
J Antimicrob Chemother. 2011 Apr;66(4):827-33. Epub 2011 Jan 19.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on